万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>肿瘤学

JNCI-Journal of the National Cancer Institute《美国国家癌症研究所杂志》 (官网投稿)

简介
  • 期刊简称JNCI-J NATL CANCER I
  • 参考译名《美国国家癌症研究所杂志》
  • 核心类别 高质量科技期刊(T2), SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子
  • 自引率1.40%
  • 主要研究方向医学-ONCOLOGY 肿瘤学

主要研究方向:

等待设置主要研究方向
医学-ONCOLOGY 肿瘤学

JNCI-Journal of the National Cancer Institute《美国国家癌症研究所杂志》(月刊). The Journal of the National Cancer Institute (print ISSN: 0027-8874, online&...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:https://academic.oup.com/jnci

3、投稿网址:http://www.editorialmanager.com/jnci/

4、官网邮箱:jnci.editorialoffice@oup.com

5、期刊刊期:月刊,一年出版12期。

202182日星期一

                                 

 

投稿须知【官网信息】

 

Journal of the National Cancer Institute

Instructions to Authors

Charges

Forms

Submit a Manuscript

Manuscript Preparation

Manuscript Checklist

Journal Policies

Charges

Open Access for Authors

Authors of Articles, Brief Communications, Reviews, MiniReviews, and Commentaries in the Journal have the option to publish their paper under the open access initiative; whereby, for a charge, their paper will be made freely available online immediately upon publication. After your manuscript is accepted the corresponding author will be required to accept a mandatory licence to publish agreement. As part of the licensing process you will be asked to indicate whether or not you wish to pay for open access. If you do not select the open access option, your paper will be published with standard subscription-based access and you will not be charged.

Open access articles are published under Creative Commons licences.

RCUK/Wellcome Trust funded authors publishing in this journal can use the Creative Commons Attribution licence (CC BY) for their articles.

Journal of the National Cancer Institute offers the option of publishing under either a standard licence or an open access licence. Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please do clarify any such requirements with your funder or institution.

Should you wish to publish your article open access, you should select your choice of open access licence in our online system after your article has been accepted for publication. You will need to pay an open access charge to publish under an open access licence.

Details of the open access licences and open access charges.

OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating.

Please note that these charges are in addition to any colour charges that may apply.

Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your institution, and ensure you account for your own local VAT correctly.

Color Figures

The print charge for color figures in the Journal of the National Cancer Institute is $600 per figure. There is no charge to publish figures in color online. You will be asked to agree to charges relating to color figures at the time of manuscript submission and acceptance.

Forms

License to Publish

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.

Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles.

Conflict of Interest

Journal policy requires that all authors of research papers, Reviews, MiniReviews, Commentaries, Correspondence, and Responses complete a Conflict of Interest disclosure form, which will be provided to authors when the manuscript is submitted. Potential Editorialists will be required to complete a Conflict of Interest disclosure form at invitation. Invitations may be withdrawn if the Editorial Board decides that potential conflicts are substantial. Authors will be asked to disclose: 1) any financial interest in or arrangement with a company whose product was used in a study or is referred to in a Review, MiniReview, opinion piece, or letter, 2) any financial interest in or arrangement with a competing company, and 3) any other financial connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated—including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. If the manuscript is published, such information may be communicated in a note following the text and references.

Submitting Manuscripts

Submission Procedures

Authors must submit manuscripts electronically via the Journal's Web-based submission system and use the Journal's Web site; submissions will not be accepted by e-mail or in hard copy.

Electronic Submission

Manuscripts may be submitted at the Journal’s online submission Web site. The submitter will indicate the files to be uploaded, and then identify these files.

See "File Types," below, for information about acceptable types. Tables should be included in the article file. Each figure should be in a separate file. Related manuscripts or abstracts should be included in the uploaded files. The submitter will be asked to enter the article's title (which may be pasted into the submission form from another document); to provide information about the authors; to initial several required statements; and to select the appropriate manuscript type, category, and classification terms.

The system will generate PDF files from the author’s original files, and the submitter will have an opportunity to approve these PDF files before they are forwarded to the editorial board. Please note that because the PDF file will replicate the formatting in the author's files, it is required that the manuscript be double-spaced. For Word files, be sure to accept all changes in the document before uploading it to the submission site, otherwise the tracked changes will be visible in the PDF file for review by the journal editors and reviewers.

The editorial office will communicate all decisions about the manuscript to the corresponding author by e-mail. Additional help and instruction are available throughout the submission process on the Web site.

File Types

All article files, for any initial submission or revised manuscript, must be in a Microsoft Word–compatible format; such formats include the Word, Word Perfect, text, and RTF formats.

Figures may be submitted in TIFF, GIF, JPG, PDF, Postscript, EPS, Word, PowerPoint, or RTF format. Avoid submitting very large files; figures should be submitted at the lowest resolution that will permit reviewers to evaluate the work. Electronic versions of figures will be used for production. If a figure file is large (as will be the case for some color figures and for photomicrographs and other figures that need to be reproduced at high resolution), the author should upload a low-resolution version of the figure with the manuscript submission; if higher-resolution files are necessary during the publication process, instructions for providing those files will be sent at that time.

Tables must be submitted in Microsoft Word format as Microsoft Word tables. Tables must be included at the end of the article file and should not be submitted as separate files.

Material that cannot be supplied electronically

Some material that the editorial board requires for the evaluation of a manuscript may not be available in electronic form or may exist in an electronic form that is incompatible with the online submission system.

Such material might include: a) figures that must be viewed at very high resolution by reviewers (but lower- resolution electronic versions are preferred whenever these will be acceptable for review); b) microarray data; or c) very large related manuscripts or related manuscripts for which the author does not have the electronic version.

In such cases, the author should complete the electronic submission process for the text of the article and for any figures, tables, or related manuscripts that are available in electronic form. Material that can be scanned should be uploaded in the Journal's Web-based submission system. Large amounts of raw data or sequences that are stored on a public or institution web-based database can be cited in the text or supplementary files using the accession numbers and/or URL (see “Sequence Information and Microarray and Proteomic Data”).

Manuscript Preparation

Manuscript Types

Specific Requirements

Author Self Archiving and Public Access

Previously Published Material

Availability of Data and Materials

Manuscript Types

Articles

Articles provide the most extensive description of new findings of major importance. An Article should contain 3000 or fewer words, not counting abstract, reference list, tables, footnotes, and figure legends. (See "Figures and Tables".) Methods are included in the word count, but some methods may be moved to an online-only Supplementary Methods section (see “Specific Requirements, Methods”).

Systematic Reviews (with or without Meta-analysis) and Meta-analyses

Articles using these study designs should be formatted like Articles (see above) and should contain 6000 or fewer words (including the Methods section, but not counting abstract, reference list, tables, footnotes, and figure legends). These studies will be classified as Reviews. The study design (eg, systematic review, meta-analysis) should be included in the title.

Brief Communications

Brief Communications are concise descriptions of new findings of general interest. A Brief Communication should contain 1000 or fewer words, not counting abstract, reference list, tables, footnotes, and figure legends. Neither a Brief Communication nor its abstract should be divided by heads and subheads. (See "Figures and Tables.")

Correspondence

Letters to the editor may express an opinion about material previously published in the Journal or express views on topics of current relevance to some aspect of cancer, but not with exclusive reference to a specific report published in a journal other than the JNCI. A letter should contain 500 or fewer words, not counting the reference list (seven references maximum), footnotes, and figure legend or table. A letter relating to work published in the Journal will ordinarily be referred to the author(s) of the original item for a response, which may be published along with the letter. Complete references should be given if the letter cites the work of others; if the letter comments on an item published in the Journal, that item must be included in the numbered reference list. (See "Figures and Tables.")

Editorials

Editorials convey opinions on any subject relevant to the Journal's concerns. They may discuss a paper in the same issue of the Journal, a recent finding published elsewhere, or a particular topic of importance. Editorials are usually solicited by the editors, but unsolicited submissions will be considered. Editorials usually contain about 1000 words, not counting reference list and notes. One table or figure will be allowed if necessary. The JNCI article being editorialized should be cited in the editorial and included in the reference list.

Commentaries

Topical items under this heading convey to the reader, in relatively nontechnical style, a summary of current activities or issues that bear on some aspect of cancer. Discussions of appropriate data analyses or of thematic issues to emerge from recent scientific meetings are examples of suitable subject areas. A Commentary usually contains 2000-4000 words, not counting abstract, reference list, tables, footnotes, and figure legends. (See "Figures and Tables".)

Reviews

A good Review provides a comprehensive overview of an area of cancer biology, epidemiology, prevention, treatment, survivorship, behavioral science, or policy. Although Reviews should be accessible to knowledgeable readers not expert in the subject area, Reviews should be prepared with the same rigor as a research paper reporting specific results. The Journal encourages high-quality systematic reviews with or without meta-analysis over narrative reviews, unless discussing a hypothesis or presenting basic information (please see The Need for Systematic Reviews in Oncology for details). Although most Reviews are solicited by the editors, unsolicited submissions are also welcome. A Review should contain 6000 or fewer words, not counting abstract, reference list, tables, footnotes, and figure legends. (See "Figures and Tables".)

MiniReviews

MiniReviews are concise Reviews that highlight timely topics in oncology of major importance that are of broad interest; they can also simplify complex topics for the broad readership. MiniReviews are not opinion pieces and should be prepared with the same rigor as a full review or meta-analysis, reporting and synthesizing specific results into a coherent overview. Some MiniReviews are solicited by the editors, but unsolicited submissions are also welcome. A MiniReview should contain 2000 or fewer words, not counting abstract, reference list, tables, footnotes, and figure legends; it should 4 or fewer figures plus tables (See "Abstract" and "Figures and Tables").

Specific Requirements

Manuscript Format

Manuscript title page, the body of the manuscript, reference list, footnotes, and figure legends must be typed double-spaced. Tables may be single- or double-spaced, although the type must be large enough and the lines of type sufficiently well spaced to be easily read.

Title Page

The title should be brief (14 words or fewer) and, except for Editorials and Correspondence, should not be in sentence form. If a letter to the editor pertains to an item published in the Journal, the title of the letter should be "Re:" followed by the title of the original item. The title page should give the full name, degree(s), and affiliation of each author and the name and address of the single author to whom correspondence and/or reprint requests are to be sent. Include the telephone number and e-mail address of the corresponding author. Authors should be aware that the individual named first in a list of authors of a paper, and his/her institutional affiliation, will be the one named in any publication-related or postpublication citation or communication by the Journal concerning the paper.

Abbreviations

Journal policy is to avoid the use of abbreviations whenever possible. If abbreviations are essential, list and define them. Author-created abbreviations are not to be used.

Abstract

Articles, Systematic Reviews (with or without Meta-analysis), Meta-analyses, Commentaries, Reviews and MiniReviews must contain an abstract of no more than 250 words; Brief Communications must contain an abstract of no more than 150 words. Abstracts should be written using complete sentences. An abstract should clearly state unique elements of the work, should be readable by nonspecialists as well as by experts in the particular field, and should concisely state all important findings of the study. All information in the abstract (including implications) must be explicitly stated in the text.

Include, as appropriate, the following headings in abstracts for Articles, Systematic Reviews (with or without Meta-analysis), and Meta-Analyses (but not for Brief Communications, Commentaries, Reviews, or MiniReviews): Background, Methods, Results, and Conclusion(s).

The Background should come from the Introduction of the paper and should note relevant previous findings, designated as those of the authors and/or other investigators. It should also state the purpose of the present paper.

The Methods should indicate all important materials or techniques used to fulfill the purpose of the study; these methods will be described more fully in the Methods section of the paper, and for each finding noted in the Results, a corresponding method should be provided in the Methods.

The Results should contain only information detailed in the Results section of the paper. All important results should be noted in the Results. (See "Statistical Methods".) The Methods must not contain results, and the Results must not contain methods.

The next section of the abstract should state any important Conclusion(s) demonstrated or suggested by the results. The Conclusion(s) should come from the Discussion section and can include any implication(s) derived as a next logical step or inference directly from the results of the study reported and other related findings from investigators mentioned in the Discussion. Implication(s), as stated in the Discussion, may suggest directions for future experimental research and/or possible clinical applications and may note a particular need for confirmatory studies or offer cautions regarding interpretation of the results.

Carefully review each statement in the abstract to ensure that the above points are satisfied.

Text

All submitted text should be typed double-spaced and should be written in standard grammatical English. (Refer to the American Medical Association Manual of Style, 10th Edition on questions of style.) Indent the first line of each paragraph. Number all pages consecutively, beginning with the title page. Dot-matrix or italicized text will not be accepted. All symbols and abbreviations should be defined. Number references, tables, and figures in the order in which they are cited in the text. References in tables should continue the sequence of numbers in the text at the point where the table is first mentioned (ie, numbering of table references should not be reserved until the end of the reference list). Articles should contain a brief introduction and three additional sections labeled Methods (or a variation of the term), Results, and Discussion.

Methods

The methods of key experiments and statistical analyses must be in the main article and not in Supplementary Methods. Methods descriptions should be succinct but sufficiently detailed to allow replication of the study by a qualified investigator. If a procedure has been previously published, a brief description should be provided in addition to the reference, especially if the procedure was modified. Authors should specify full names, types, amounts, and sources of reagents (giving complete names and locations of suppliers); full names as well as standard abbreviations of labeled compounds and isotopes used for labeling; concentrations of solutions; and reaction conditions (eg, incubation times and temperatures). In addition, techniques and procedures used should be accurately named, clearly and thoroughly explained, referenced when appropriate, and organized under appropriate subheadings. The Methods section must be complete and should include the methodology corresponding to each of the end points presented in the Results. Authors should specify experimental conditions that limit the generalizability of the Results.

For clinical trials, authors should clearly define and explain the purpose of the study, study design, numbers of patients, clinical staging of disease, type and sequence of treatments given before and during the study, time points for evaluation of response, duration of follow-up, end points used (eg, overall survival, disease-free survival), specific outcomes assessed, and methods of assessment. This requirement should be met, even when the major focus of a study is not the clinical trial to which it is related (eg, association of gene, messenger RNA, or protein expression with disease therapy or prognosis). (See also "Clinical Trials".)

Where appropriate, clinical and epidemiologic studies should be analyzed to see if there is an effect of sex or any of the major ethnic groups. If there is no effect, it should be so stated in Results.

The Methods section should contain a "Statistical Analysis" subsection, where applicable. (See "Statistical Methods".)

The Methods sections of Articles are included in the word count (see “Articles”). Therefore, if meeting the requirements causes the article to exceed the word limit, general methods that do not specifically describe the key experiments and analyses may be moved to online-only supplementary materials (see “Online Data Supplements”).

Statistical Methods

The methods of statistical analysis should be described in sufficient detail that a knowledgeable reader could reproduce the analysis if the data were available. The word "significant" should be used only if a result is statistically significant. A P value or confidence interval should be cited in the abstract and in the text for any statistically significant finding reported; wherever possible, exact P values should be given. All tests of statistical significance should be two sided, and the abstract and the text should so state. Outcome variables should generally be given as point estimates, with 95% confidence intervals rather than standard deviations or standard errors.

Reporting Guidelines

Authors are encouraged to follow published standard reporting guidelines for the study discipline (eg, ARRIVE for animal studies; REMARK for prognostic markers; STARD for diagnostic markers; MOOSE for meta-analyses of observational studies in medicine Donna F. Stroup et al. JAMA. 2000;283:2008-2012; PRISMA for systematic reviews and meta-analyses of health care interventions; STROBE for cohort and case-control studies; STROBE Extension to Genetic Association studies: STrengthening the REporting of Genetic Association studies (STREGA) Little J, Higgins J, Ioannidis JPA, Moher D, Gagnon F, et al. PLoS Med 2009; 6: e22. doi:10.1371/journal.pmed.1000022; and MIQE for studies that use qPCR experiments) and to refer to Simon RM, Paik S, and Hayes DF J Natl Cancer Inst 2009;101:1446-1452 as a guide to studies that evaluate tumor markers, Hollingshead MG J. Natl Cancer Inst 2008;100:1500-1510 as a guide to rodent model studies and to Table 3 in Dupuy A and Simon RM J. Natl Cancer Inst 2007; 99:147-57 as a guide to microarray-based studies for clinical outcomes. Authors are encouraged to use the SAMPL Guidelines as a guide for reporting statistical analyses.

Clinical Trials

In reporting randomized clinical trials, authors must comply with published CONSORT guidelines. The recommended checklist must be completed and provided to the Journal at the time of manuscript submission. The recommended trial flow diagram should be presented as a figure (usually Fig. 1). Because manuscripts describing clinical trials are generally submitted as Articles, the allowable number of figures and tables for this format will be increased by one to accommodate the flow diagram. Thus, Articles describing clinical trials may have up to nine figures and tables. (See also "Methods".)

Authors of randomized Phase II/III trials must provide to the Journal at the time of submission a brief description of the statistical plan of the original study that includes the primary and secondary endpoints, power calculation, and sample size.

Clinical trials should be registered in accordance with the criteria outlined by the International Committee of Medical Journal Editors, including the December 2017 update. Authors should provide the trial registration number in the Methods section and provide a link to the trial registration, to be cited as a reference. Authors should also follow the guidelines for data sharing therein.

Consent and Approval

Manuscripts reporting on biomedical studies involving human subjects must include explicit assurance that written informed consent was obtained from each subject or from his or her guardian. Such manuscripts must include a statement that the human investigations were performed after approval by a local institutional review board and in accord with an assurance filed with and approved by the U.S. Department of Health and Human Services, where appropriate.

When a pedigree or family tree is depicted, assurance must be given that written informed consent was obtained from each living individual represented. In addition, authors must state in writing that they have not modified the pedigree or family tree to avoid potential identification of the family or its members. In rare instances, the editorial board may permit modification of a pedigree to preserve patient anonymity if the authors present compelling reasons for making such modifications and the changes made do not affect interpretation of the data. In such cases, authors must provide the original, unmodified data for examination by peer reviewers and the editorial board and must include a statement in the manuscript explaining that the pedigree has been modified.

Animal Welfare

Any study involving experiments with animals must state that their care was in accord with institution guidelines. Where applicable, the dose and schedule of anesthetics and analgesics should be reported.

……

更多详情:

https://academic.oup.com/jnci/pages/General_Instructions


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭